Navigation Links
Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
Date:6/5/2008

- Phase 1b Study is First to Show RNA Aptamer Drug:Antidote Pair Offers Rapid Reversal of Anticoagulant Effect in Patients with Coronary Artery

Disease -

DURHAM, N.C., June 5 /PRNewswire/ -- Regado Biosciences today announced the journal Circulation has published clinical data from the Company's REG1 anticoagulation system Phase 1b dose-escalation study. REG1 is a two-component system comprised of an aptamer-based anticoagulant, RB006, and its matched antidote, RB007, which binds to and neutralizes RB006. The published study is the first to show in patients that RB006 effectively inhibited the activity of Factor IXa, a protein essential to blood clotting and that RB006's activity was reversed rapidly and safely by RB007.

The article, titled, "A Phase 1b Randomized Study of Antidote-Controlled Modulation of Factor IXa Activity in Patients with Stable Coronary Artery Disease", was authored by clinical researchers from the Duke Clinical Research Institute and Regado. The study showed an intravenous (IV) bolus injection of RB006 achieved a prompt, consistent, and dose-dependent prolongation of activated partial thromboplastin time (aPTT), a well-accepted surrogate marker of the blood's ability to clot. In addition, a 1 mg/kg dose of RB006 resulted in essentially complete Factor IXa inhibition. The study also demonstrated an IV bolus injection of RB007 administered in a 2:1 antidote:drug ratio successfully reversed prolonged aPTT within a median of one minute, with no rebound for up to seven days. There were no major bleeding or other serious adverse events observed in the study, which included 19 subjects who received dual antiplatelet therapy.

"The data published in Circulation provide further evidence of the REG1 system's ability to rapidly and predictably anticoagulate and then to reverse this effect as needed in a reproducible manner. The results also show the pharmacologic data translated well from heal
'/>"/>

SOURCE Regado Biosciences
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
2. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
3. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
4. Magellan Biosciences Companies to Feature Automated Products and New Tests for MRSA at the American Society for Microbiology Meeting, Booth 743
5. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
6. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
7. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
8. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
9. Neurocrine Biosciences Reports First Quarter 2008 Results
10. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
11. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire/ –  ... PHG AEX: PHIA) today announced ... Society of Cardiology (ESC) Congress 2014 ... range of its cardiology solutions serving clinicians and ... prevention and diagnosis, to treatment, ...
(Date:8/28/2014)... Long, P.A.: , Do you, or did you, ... , Did you purchase your shares before September 10, 2013, ... , Did you lose money in your investment in Lannett ... rights? Rigrodsky & Long, P.A. , ... , announces that a complaint has been filed in the United ...
(Date:8/28/2014)... 28, 2014 Reportlinker.com announces that ... in its catalogue: Needle-Free Delivery: ... http://www.reportlinker.com/p02332847/Needle-Free-Delivery-Technology-and-Market-Forecast-2014-2024.html Report ... and commercial prospects What does the future ... brand new report shows you the potential ...
Breaking Medicine Technology:Philips Spotlights New Cardiology Solutions and Unveils Ultrasound Technology at European Society of Cardiology Congress 2014 2Philips Spotlights New Cardiology Solutions and Unveils Ultrasound Technology at European Society of Cardiology Congress 2014 3Philips Spotlights New Cardiology Solutions and Unveils Ultrasound Technology at European Society of Cardiology Congress 2014 4Philips Spotlights New Cardiology Solutions and Unveils Ultrasound Technology at European Society of Cardiology Congress 2014 5Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 2Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 3Needle-Free Delivery: Technology and Market Forecast 2014-2024 2Needle-Free Delivery: Technology and Market Forecast 2014-2024 3Needle-Free Delivery: Technology and Market Forecast 2014-2024 4Needle-Free Delivery: Technology and Market Forecast 2014-2024 5Needle-Free Delivery: Technology and Market Forecast 2014-2024 6Needle-Free Delivery: Technology and Market Forecast 2014-2024 7Needle-Free Delivery: Technology and Market Forecast 2014-2024 8Needle-Free Delivery: Technology and Market Forecast 2014-2024 9Needle-Free Delivery: Technology and Market Forecast 2014-2024 10Needle-Free Delivery: Technology and Market Forecast 2014-2024 11Needle-Free Delivery: Technology and Market Forecast 2014-2024 12Needle-Free Delivery: Technology and Market Forecast 2014-2024 13Needle-Free Delivery: Technology and Market Forecast 2014-2024 14Needle-Free Delivery: Technology and Market Forecast 2014-2024 15Needle-Free Delivery: Technology and Market Forecast 2014-2024 16Needle-Free Delivery: Technology and Market Forecast 2014-2024 17Needle-Free Delivery: Technology and Market Forecast 2014-2024 18
... Food and Drug,Administration (FDA) announced the entry ... PharmaFab Inc., its subsidiary, PFab,LP, and two ... McMahen, PFab's vice president of scientific affairs, ... prescription and,over-the-counter drug products. The products are ...
... ROCKVILLE, Md., April 21, 2007-Genentech and FDA ... tracheoesophageal (TE) fistula formation in a recent,clinical ... lung,cancer (SCLC). This multicenter, non-randomized, single-arm phase,II ... plus,Avastin. There have been two confirmed serious ...
Cached Medicine Technology:Major Manufacturer of Unapproved and Adulterated Drugs 2Major Manufacturer of Unapproved and Adulterated Drugs 3
(Date:8/29/2014)... 2014 Healthpointe is pleased to ... Therapy students via Clinical Rotations. Physical ... shadowing Healthpointe providers and specialists throughout their daily ... clinical experience and learn professional preparation. ... insight into several patient care techniques and expand ...
(Date:8/29/2014)... 2014 Healthpointe is pleased to announce ... their practice. Dr. Chuang garners extensive experience in the ... arthroscopic and reconstructive treatments of the knees, hips, and ... general and sports-related orthopedic needs. , Dr. ... As an Orange County native, he graduated with two ...
(Date:8/29/2014)... Healthpointe Medical Group, one of Southern California’s ... LAXMed. The medical center is less than 2 miles from ... the 405 freeway. , The LAX clinic marks the ... is located at: 8610 S. Sepulveda Blvd., Suite 204 Los ... LAX office will provide the same comprehensive services as Healthpointe’s ...
(Date:8/29/2014)... released yesterday by the Mental Health Commission of ... training and education that police personnel receive. , ... for Canada,s police community, and today,s report builds ... and people with mental illnesses," says Queen,s adjunct ... interest in the area of police psychology. "This ...
(Date:8/29/2014)... 29, 2014 A team of experts ... is on its way to the 2014 National Safety ... Convention Center to exhibit and demonstrate a suite of ... industrial environments. Etymotic’s safety earphones and high-definition earplugs are ... at the show. , The company’s HD5 high-definition, ...
Breaking Medicine News(10 mins):Health News:Healthpointe is Now Offering Clinical Rotations for Chapman University Physical Therapy Students 2Health News:Healthpointe is Honored to Induct Orthopedic Surgeon into Their Team 2Health News:Healthpointe Obtains a New Medical Clinic in the LAX Area 2Health News:Report advocates improved police training 2Health News:Etymotic’s Safe Listening Earphones and Earplugs Headed For The 2014 NSC Safety Expo 2
... identified a receptor on the surface of cells that may ... common and most deadly type of brain cancer. , ... all human glioblastoma cells, may prove to be an appropriate ... to a study led by researchers in the Duke Department ...
... plans to exchange bonds for stock jeopardize shareholder interests?TEQUESTA, ... D. Bell, Chief Restructuring Officer, and the Board of ... of the Cancer Cure Coalition (CCC), personally holding a ... holds 1,200 shares, expressed deep concern over a proposed ...
... Officer David Brennan was elected board chairman of the Pharmaceutical ... annual meeting.In a speech to the meeting attendees, Brennan called ... care system to work together in a new collaborative and ... , ...
... at Apollo Hospital Treats Six and Preps Eight Patients ... (Nasdaq: ARAY ), a global leader in ... patients in India have been treated using CyberKnife radiosurgery. ... Specialty Cancer Hospital in Chennai, India, treated six patients ...
... from ravages of neurodegenerative disease , , FRIDAY, April 3 ... possible way to prevent brain cells from falling victim ... is still in the preliminary stages, and the researchers ... Still, a Huntington,s disease expert said the findings could ...
... DULUTH, Ga., April 3 Innovative Architects, a ... their employees and clients to join the 2009 19th Annual ... Station on May 9th, 2009. For every employee or client ... Innovative Architects will make a donation to the Susan G. ...
Cached Medicine News:Health News:Cellular target may prove useful in treating deadly brain tumors 2Health News:AstraZeneca's David Brennan Elected PhRMA Board Chairman 2Health News:AstraZeneca's David Brennan Elected PhRMA Board Chairman 3Health News:AstraZeneca's David Brennan Elected PhRMA Board Chairman 4Health News:First Patients Treated in India Using CyberKnife Radiosurgery 2Health News:First Patients Treated in India Using CyberKnife Radiosurgery 3Health News:First Patients Treated in India Using CyberKnife Radiosurgery 4Health News:Scientists Uncover New Weapon Against Huntington's 2Health News:Innovative Architects Calling on Clients and Employees to Support the 2009 19th Annual Komen Atlanta Race for the Cure 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: